Description of Business and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Aug. 18, 2022	Jul. 06, 2021	Dec. 31, 2023	Dec. 31, 2022
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Aggregate proceeds from issuance of private placement				$ 174
Accumulated deficit			$ 530,752	$ 383,790
Cash, cash equivalents and marketable securities			436,300
Follow-on Offering
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Net proceeds from sale of common stock in public offering		$ 257,000
Stock Issued During Period, Shares, New Issues		5,468,250
Common stock per share		$ 47
Underwriters
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues		713,250
Private Placement | Vertex Pharmaceuticals Incorporated
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Aggregate proceeds from issuance of private placement		$ 2,300
Stock Issued During Period, Shares, New Issues		49,928
Common stock per share		$ 47
Private Investment in Public Equity "PIPE"
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues	2,769,228
Common stock per share	$ 26
Pre-funded warrant purchase price	25.9999
Pre-funded warrants per share	$ 0.0001
Offering expenses	$ 149,800
Minimum pre-funded warrants, exercise	4.99%
Increase or decrease pre-funded warrants, maximum	19.99%
Prior notice period, minimum	61 days
Pre-funded warrants, exercised			$ 0
Pre-funded warrants outstanding	3,000,000		3,000,000